BETA · In development—Rankings and features improve every week.Spotted an error?Tell us →
Sign in / Register

Truvian Health

Active#7 worldwide · In-vitro diagnostics

Estimated valuation · In-vitro diagnostics · United States

Builds an automated benchtop blood analyser that runs chemistry, immunoassay and haematology tests from one small sample in retail and clinic settings.

HQUnited States
Last roundFinancing round (series not stated) · Jul 2024

Estimated valuation

AI · In-vitro diagnostics ranking (worldwide)
≈ USD 380MUSD 250–570M · Hundreds of M$
Anchor
Last known equity round: Financing round (series not stated) · USD 74M · Jul 2024

An indicative editorial estimate produced by AI, imperfect by nature: neither a financial valuation nor investment advice. Only the market sets a company’s value. Method

Uback rankings

How the AI ranks →
RankingTierRankEditionNext update
In-vitro diagnostics · worldwideTop 25#7Edition 0 · Oct 202612 Apr 2027
Rank historyOct 2026 · #7 In-vitro diagnosticsFirst edition: no movements yet.

Funding history

DateRoundAmountTypeInvestors
Jul 2024Financing round (series not stated)USD 74MEquityWittington Ventures, Great Point Ventures

Rounds as cited by Uback’s rankings. Equity, debt and grants are shown separately; only equity rounds count towards the valuation anchor.

Independent analyses

By industry professionals & analysts

Industry professionals and financial analysts can publish their own analysis of Truvian Health as a PDF. It must answer at least one of these four questions, and stick to them:

AI valuation: $380MUndervalued or overvalued?
Versus competitorsHow does it compare?
Who should acquire itStrategic buyers, and why
Who should it acquireAcquisition targets, and why
Publish an analysisName, role and LinkedIn shown · public sources only

Analyses are the opinion of their authors, not of Uback. They are checked before publication.

Comparable companies in in-vitro diagnostics

Full in-vitro diagnostics ranking →

Last updated: Oct 2026Report an error

Uback is a content publisher and an aggregator of non-binding expressions of interest. It provides no investment advice, receives no mandate and takes part in no transaction. Rankings, ranges and brackets are editorial estimates produced by AI, purely indicative.